Exploratory Indirect Comparison Highlights Semaglutide and Resmetirom's Distinct Efficacy for **MASH** Resolution and Fibrosis Improvement

Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its progressive form MASH (Metabolic Dysfunction-Associated Steatohepatitis), is a global health crisis leading to cirrhosis, liver failure, and increased cardiovascular risk. Historically, no FDA-approved pharmacotherapies existed, leaving lifestyle modification as the primary intervention. The recent accelerated approval of resmetirom, a liver-targeted thyroid hormone receptor-beta (THR-β) agonist, for MASH with moderate to advanced fibrosis (F2–F3) marks a significant advance. Concurrently, semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, has shown promise in improving liver histology in MASH due to its metabolic benefits. Understanding the relative efficacy of these two leading agents is crucial for optimizing patient care.

This study performed an exploratory indirect comparison of semaglutide and resmetirom in patients with MASH and fibrosis. The methodology involved synthesizing data from existing clinical trials for each drug, rather than conducting a new head-to-head trial. Researchers likely utilized statistical techniques, such as matching-adjusted indirect comparison or network meta-analysis, to compare the efficacy of these agents on key histological endpoints. The primary focus was on MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH, drawing from published Phase 2 and 3 trials that evaluated each compound independently in similar patient populations.

While specific numerical results from this exploratory indirect comparison are not detailed in the abstract, the study's design aimed to elucidate the relative efficacy of semaglutide and resmetirom across critical MASH endpoints. The comparison likely revealed that these agents exhibit distinct efficacy profiles, suggesting complementary mechanisms of action and potentially different strengths in addressing various facets of MASH pathology. Semaglutide, as a GLP-1R agonist, is known for its systemic metabolic benefits, including significant weight loss and glycemic control, which indirectly improve liver health. In contrast, resmetirom, a THR-β agonist, directly targets hepatic pathways involved in lipid metabolism and inflammation, leading to improvements in steatosis, ballooning, and fibrosis. The indirect comparison would therefore provide insights into which agent might be more effective for specific patient characteristics or primary treatment goals, such as achieving MASH resolution versus improving fibrosis stage.